WGS Healthcare

GeneDx Holdings Corp.

$68.64+7.10%

Price as of close on Nov 3, 2026 · Financials updated Oct 1, 2026

Basics

Sector: Healthcare
Industry: Diagnostics & Research
Country: United States
Market cap: 2.0B USD
Enterprise value: 1.9B USD
Full-time employees: 1,300

Overall health

Strength: growing faster than most peersgrowing faster than peers
Drawback: less profitable than most peersless profitable than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Drawback: higher risk than most peers: its share price swings more than most peers’ (beta 2.01 vs a peer median of 0.63)higher risk: bigger price swings (beta 2.01 vs peers 0.63)

Ranks #995 of 1,157 healthcare companies (bottom 15%)

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 153% from December 2022 to July 2026.
GeneDx had 153% more shares at July 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.GeneDx had 153% more shares at July 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.
Earnings slid into a loss. Loss per share this year after a profit last year.
GeneDx made a loss per share in its latest year after a profit the year before.
Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, GeneDx looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Growing fast, still losing money. Revenue grew faster than 83% of peers, at an operating loss.
Revenue grew faster than 83% of peers, but the business runs at an operating loss (margin -20%).

StockQuotient Score

29/ 100

Oct 5 29 → Nov 4 29

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-5.2%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-4.1%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-3.7%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield11.9%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

65/100

Moderate

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

12-month revenue up 2.7%

Why

Stronger than most peers on:

▲ 3-yr revenue
▲ Revenue growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

Earnings per share turned from a profit to a loss33% base weight · Z-score -1.99Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth24.3%

SEC filings · 3 years to Jun 2026Reported value33% base weight · Z-score 2.20Sector median: 0.0584 · MAD: 0.0840

Revenue growth25.4%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 1.98Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

22/100

Weak

3/3 inputs reported · High confidence

Since last quarter: ▼ Weaker

Operating margin fell 5.4 points to -20.3%

Why

Weaker than most peers on:

▼ ROA
▼ ROIC
▼ Operating margin

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin-20.3%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -2.25Sector median: 0.0706 · MAD: 0.1217

Return on assets-22.1%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -4.43Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-25.7%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -3.03Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin69.4%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-43.5%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Higher

Higher relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why it changed since the Oct 27, 2026 close: Safety percentile 20 → 21

Peer companies moved+1

Each step re-scores the company against its peers as they were on Oct 28, 2026; the parts add up to the change. Price effects on EBITDA yield are approximate.

Why

Weaker than most peers on:

▼ Beta
▼ Debt / equity

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta2.01

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -4.09Sector median: 0.6250 · MAD: 0.3380

Current ratio3.30×

SEC filings · latest balance sheetReported value33% base weight · Z-score 0.52Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.41×

SEC filings · latest balance sheetReported value33% base weight · Z-score -0.92Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about GeneDx

Is GeneDx getting weaker?: Its latest SEC filing (Aug 3, 2026) got weaker in some ways: operating margin fell 5.4 points to -20.3%. Its overall score is unchanged at 29/100 since Oct 28, 2026.
How is GeneDx valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -5.2% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -5.2% vs peers 1.5% (weaker than 100% of peers).
Is GeneDx growing?: Yes, faster than most of its peers. Growth scores 65/100 against 1,393 healthcare peers. 3-year revenue growth 24.3% vs a peer median of 5.8% (stronger than 84% of peers).3-year revenue growth 24.3% vs peers 5.8% (stronger than 84% of peers).
How profitable is GeneDx?: Less profitable than most of its peers. Profitability scores 22/100 against 1,393 healthcare peers. Return on assets -22.1% vs a peer median of 1.7% (weaker than 82% of peers).Return on assets -22.1% vs peers 1.7% (weaker than 82% of peers).
How risky is GeneDx?: Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Beta 2.01 vs a peer median of 0.63 (weaker than 95% of peers).Beta 2.01 vs peers 0.63 (weaker than 95% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 3, 2026 · compared with the quarter ended Mar 31, 2026

Got weaker

Operating margin fell 5.4 points to -20.3%

	Previous quarter	Latest quarter	Change
Revenue (12 months)	442.7M USD	454.4M USD	+2.7%
Net income (12 months)	−77.8M USD	−106.3M USD	+36.7%
Operating margin	-14.9%	-20.3%	−5.4 pts
Free cash flow (12 months)	−28.7M USD	−75.8M USD	+164.5%
Debt	100.0M USD	100.0M USD	0.0%
Cash	93.9M USD	60.3M USD	−35.8%
Shares outstanding	29.7M	29.8M	+0.5%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Diagnostics & Research · 26 companies

Valuations in Diagnostics & Research are within their usual range since Nov 2018.

53% of months since Nov 2018 were valued lower than now.
24% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +109% vs the whole market, against a usual +111%.

Nov 2018Shaded: most expensive fifth of its range2026

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Gross margin	-7.8%	-11.4%	44.4%	63.6%	69.7%	▲ 6.1 pts
Operating margin	-210.3%	-284.5%	-89.2%	-7.6%	-3.1%	▲ 4.5 pts
Net margin	-115.6%	-233.9%	-86.8%	-17.1%	-4.9%	▲ 12 pts
Return on assets (ROA)	-44.3%	-111.8%	-42.0%	-12.5%	-4.0%	▲ 8.5 pts
Return on equity (ROE)	-63.2%	-216.4%	-77.1%	-21.3%	-6.8%	▲ 14 pts
Free cash flow margin	-94.2%	-139.0%	-91.5%	-11.1%	3.3%	▲ 14 pts
Current ratio	4.77×	1.47×	3.10×	3.61×	2.46×	▼ 32%
Quick ratio	4.44×	1.38×	2.95×	3.42×	2.34×	▼ 32%
Debt to equity	0.03×	0.04×	0.25×	0.23×	0.18×	▼ 22%
Interest coverage	-157.37×	-208.19×	—	—	—	—

WGS price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: growing faster than most peersgrowing faster than peers

Drawback: less profitable than most peersless profitable than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Drawback: higher risk than most peers: its share price swings more than most peers’ (beta 2.01 vs a peer median of 0.63)higher risk: bigger price swings (beta 2.01 vs peers 0.63)

Ranks #995 of 1,157 healthcare companies (bottom 15%)

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 153% from December 2022 to July 2026.

GeneDx had 153% more shares at July 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.GeneDx had 153% more shares at July 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.

Earnings slid into a loss. Loss per share this year after a profit last year.

GeneDx made a loss per share in its latest year after a profit the year before.

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, GeneDx looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Growing fast, still losing money. Revenue grew faster than 83% of peers, at an operating loss.

Revenue grew faster than 83% of peers, but the business runs at an operating loss (margin -20%).

Questions investors ask about GeneDx

Is GeneDx getting weaker?

Its latest SEC filing (Aug 3, 2026) got weaker in some ways: operating margin fell 5.4 points to -20.3%. Its overall score is unchanged at 29/100 since Oct 28, 2026.

How is GeneDx valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -5.2% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -5.2% vs peers 1.5% (weaker than 100% of peers).

Is GeneDx growing?

Yes, faster than most of its peers. Growth scores 65/100 against 1,393 healthcare peers. 3-year revenue growth 24.3% vs a peer median of 5.8% (stronger than 84% of peers).3-year revenue growth 24.3% vs peers 5.8% (stronger than 84% of peers).

How profitable is GeneDx?

Less profitable than most of its peers. Profitability scores 22/100 against 1,393 healthcare peers. Return on assets -22.1% vs a peer median of 1.7% (weaker than 82% of peers).Return on assets -22.1% vs peers 1.7% (weaker than 82% of peers).

How risky is GeneDx?

Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Beta 2.01 vs a peer median of 0.63 (weaker than 95% of peers).Beta 2.01 vs peers 0.63 (weaker than 95% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

442.7M USD

454.4M USD

+2.7%

Net income (12 months)

−77.8M USD

−106.3M USD

+36.7%

Operating margin

-14.9%

-20.3%

−5.4 pts

Free cash flow (12 months)

−28.7M USD

−75.8M USD

+164.5%

Debt

100.0M USD

100.0M USD

0.0%

Cash

93.9M USD

60.3M USD

−35.8%

Shares outstanding

29.7M

29.8M

+0.5%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Gross margin

-7.8%

-11.4%

44.4%

63.6%

69.7%

▲ 6.1 pts

Operating margin

-210.3%

-284.5%

-89.2%

-7.6%

-3.1%

▲ 4.5 pts

Net margin

-115.6%

-233.9%

-86.8%

-17.1%

-4.9%

▲ 12 pts

Return on assets (ROA)

-44.3%

-111.8%

-42.0%

-12.5%

-4.0%

▲ 8.5 pts

Return on equity (ROE)

-63.2%

-216.4%

-77.1%

-21.3%

-6.8%

▲ 14 pts

Free cash flow margin

-94.2%

-139.0%

-91.5%

-11.1%

3.3%

▲ 14 pts

Current ratio

4.77×

1.47×

3.10×

3.61×

2.46×

▼ 32%

Quick ratio

4.44×

1.38×

2.95×

3.42×

2.34×

▼ 32%

Debt to equity

0.03×

0.04×

0.25×

0.23×

0.18×

▼ 22%

Interest coverage

-157.37×

-208.19×

—